Dr. Luke on Treatment Options in Metastatic Melanoma


Jason J. Luke, MD, FACP, discusses the treatment landscape of metastatic melanoma.

Jason J. Luke, MD, FACP, associate professor of medicine, Division of Hematology/Oncology, director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program, University of Pittsburgh Medical Center Hillman Cancer Center, discusses the treatment landscape of metastatic melanoma.

This space has seen rapid growth over the past 10 years, explains Luke. In the past, treatment was limited to chemotherapy and interleukin-2.

A number of agents have been approved for the treatment of patients with metastatic disease, including combinations of BRAF and MEK inhibitors, as well as immunotherapy with PD-1 inhibitors alone or in combination with CTLA-4 inhibitors, explains Luke.

These novel treatments have shown an overall survival benefit in the metastatic setting. Now, the field has 5-year overall survival data suggesting that at least 50% of patients who develop metastatic melanoma will live for at least 5 years, concludes Luke.

<<< View more from the 2019 Chemotherapy Foundation Symposium

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH